2020-11-12,"Immunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020"
2020-10-20,"SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors"
2020-10-14,Defiance ETFs launches the first SPAC ETF
2020-10-06,Alexion Pharmaceuticals Expects To Hike Its 2020 Sales Guidance; ALXN Stock Rises
2020-09-15,"Hedge Funds Are Piling Into Immunovant, Inc. (IMVT)"
2020-09-07,"How Many Immunovant, Inc. (NASDAQ:IMVT) Shares Do Institutions Own?"
2020-09-04,"Immunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares"
2020-09-02,"Immunovant, Following Rival's Acquisition News, Prices Stock Offering"
2020-09-02,Immunovant Announces Pricing of Public Offering
2020-08-25,"Ligand OmniAbÂ® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis"
2020-08-25,"Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis"
2020-08-24,Immunovant Appoints Michael Elliott Chief Scientific Officer
2020-08-13,"SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors"
2020-08-12,"Immunovant Reports Financial Results for the Quarter Ended June 30, 2020"
2020-07-12,"Did Hedge Funds Make The Right Call On Immunovant, Inc. (IMVT) ?"
2020-06-29,"Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis"
2020-06-08,"Hedge Funds Have Never Been This Bullish On Immunovant, Inc. (IMVT)"
2020-05-14,Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement
2020-04-16,"Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares"
2020-04-14,Immunovant Announces Pricing of $121.2 Million Public Offering
2020-03-30,"Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease"
2020-03-10,"Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director"
2020-03-03,Orchestra BioMed Adds Seasoned Biotech Executive Pamela Yanchik Connealy to Board of Directors
2020-02-14,"Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019"
2020-02-10,Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference
